1. Paleari L, Pesce S, Rutigliani M, Greppi M, Obino V, Gorlero F, et al. New insights into endometrial cancer. Cancers (Basel). 2021;13(7).
2. American Cancer Society. Key Statistics for Endometrial Cancer. 2024. https://www.cancer.org/cancer/types/endometrial-cancer/about/key-statistics.html
3. American Cancer Society. Endometrial Cancer Risk Factors. 2019. https://www.cancer.org/cancer/types/endometrial-cancer/causes-risks-prevention/risk-factors.html
4. Ignatov A, Ortmann O. Endocrine risk factors of endometrial cancer: Polycystic ovary syndrome, oral contraceptives, infertility, tamoxifen. Cancers (Basel). 2020;12(7):1–10.
5. Doherty MT, Sanni OB, Coleman HG, Cardwell CR, Glenn McCluggage W, Quinn D, et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS One. 2020;15(4):1–21.
6. Van Den Heerik ASVM, Horeweg N, De Boer SM, Bosse T, Creutzberg CL. Adjuvant therapy for endometrial cancer in the era of molecular classification: Radiotherapy, chemoradiation and novel targets for therapy. Int J Gynecol Cancer. 2021;31(4):594–604.
7. Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388(23):2145–58.
8. Hussain HU, Burney MH, Rehan ST, Hasan MM. Dostarlimab: A breakthrough in the field of oncology. Ann Med Surg (Lond). 2022 Jul 5;80:104046. doi: 10.1016/j.amsu.2022.104046..
9. Di Donato V, Giannini A, Bogani G. Recent Advances in Endometrial Cancer Management. J Clin Med. 2023;12(6):10–1.
10. Bogani G, Mariani A, Paolini B, Ditto A, Raspagliesi F. Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells. Gynecol Oncol. 2019;153(3):670–5. https://doi.org/10.1016/j.ygyno.2019.02.027
11. Bellati F, Napoletano C, Gasparri ML, Visconti V, Zizzari IG, Ruscito I, et al. Monoclonal antibodies in gynecological cancer: A critical point of view. Clin Dev Immunol. 2011;2011(Table 1).
12. Stenger M. Dostarlimab-gxly With Chemotherapy for Endometrial Cancer. ASCO Post. 2023. https://ascopost.com/issues/september-10-2023/dostarlimab-gxly-with-chemotherapy-for-endometrial-cancer/
13. Rubio-Pérez J, Hernández R, Hernández T, Doger B, Casado V, Moreno V. Dostarlimab for the treatment of endometrium cancer and other solid tumors. Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.
14. Andres Redondo AG. Dostarlimab for the treatment of advanced endometrial cancer. Expert Rev Clin Pharmacol. 2022;15(1).